Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;21(1):3-22.
doi: 10.1111/adb.12314. Epub 2015 Oct 4.

Neural substrates of cue reactivity: association with treatment outcomes and relapse

Kelly E Courtney  1 , Joseph P Schacht  2 , Kent Hutchison  3 , Daniel J O Roche  1 , Lara A Ray  1   4
Affiliations
Review

Neural substrates of cue reactivity: association with treatment outcomes and relapse

Kelly E Courtney et al. Addict Biol. 2016 Jan.

Abstract

Given the strong evidence for neurological alterations at the basis of drug dependence, functional magnetic resonance imaging (fMRI) represents an important tool in the clinical neuroscience of addiction. fMRI cue-reactivity paradigms represent an ideal platform to probe the involvement of neurobiological pathways subserving the reward/motivation system in addiction and potentially offer a translational mechanism by which interventions and behavioral predictions can be tested. Thus, this review summarizes the research that has applied fMRI cue-reactivity paradigms to the study of adult substance use disorder treatment responses. Studies utilizing fMRI cue-reactivity paradigms for the prediction of relapse and as a means to investigate psychosocial and pharmacological treatment effects on cue-elicited brain activation are presented within four primary categories of substances: alcohol, nicotine, cocaine and opioids. Lastly, suggestions for how to leverage fMRI technology to advance addiction science and treatment development are provided.

Keywords: Addiction; cue reactivity; fMRI; medication development; substance use disorder; treatment.

PubMed Disclaimer

References

    1. Bach P, Vollsta Dt-Klein S, Kirsch M, Hoffmann S, Jorde A, Frank J, Charlet K, Beck A, Heinz A, Walter H, Sommer WH, Spanagel R, Rietschel M, Kiefer F. Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: A functional imaging study in alcohol dependent subjects. Eur Neuropsychopharmacol. 2015 (Epub ahead of print) - PubMed
    1. Baxter MG, Murray EA. The amygdala and reward. Nat Rev Neurosci. 2002;3:563–573. - PubMed
    1. Bechara A. Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat Neurosci. 2005;8:1458–1463. - PubMed
    1. Beck A, Wustenberg T, Genauck A, Wrase J, Schlagenhauf F, Smolka MN, Mann K, Heinz A. Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. Arch Gen Psychiatry. 2012;69:842–852. - PubMed
    1. Berridge K, Kringelbach M. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl) 2008;199:457–480. - PMC - PubMed

Publication types